SAMUEL WEDES: Open Payments
NPI 1194031062 · LIVONIA, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,513 in 134 payments from 20 companies in 2025. Trend: 2023 $20,462 · 2024 $360 · 2025 $2,513
Food & beverage: $2,401Education: $111
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 17 | $294 |
| E.R. Squibb & Sons, L.L.C. | 13 | $290 |
| Teva Pharmaceuticals USA, Inc. | 7 | $246 |
| ABBVIE INC. | 12 | $216 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $157 |
| Collegium Pharmaceutical, Inc. | 9 | $155 |
| Axsome Therapeutics, Inc. | 10 | $146 |
| Corium, LLC | 10 | $127 |
| Neurocrine BioSciences, Inc. | 6 | $124 |
| Alkermes, Inc. | 4 | $119 |
Products named: REXULTI, COBENFY, VRAYLAR, CAPLYTA, Jornay PM, UZEDY, Azstarys, INGREZZA.
Industry payments across MI — which companies pay providers there.
